188 related articles for article (PubMed ID: 9733667)
1. Comparative pharmacokinetics of oral and intravenous ifosfamide/mesna/methylene blue therapy.
Aeschlimann C; Küpfer A; Schefer H; Cerny T
Drug Metab Dispos; 1998 Sep; 26(9):883-90. PubMed ID: 9733667
[TBL] [Abstract][Full Text] [Related]
2. Urine mesna excretion after intravenous and oral dosing in ifosfamide-treated children.
Goren MP; Epelman S; Bush DA
Cancer Chemother Pharmacol; 2004 Sep; 54(3):237-40. PubMed ID: 15184993
[TBL] [Abstract][Full Text] [Related]
3. Urinary proton magnetic resonance studies of early ifosfamide-induced nephrotoxicity and encephalopathy.
Foxall PJ; Singer JM; Hartley JM; Neild GH; Lapsley M; Nicholson JK; Souhami RL
Clin Cancer Res; 1997 Sep; 3(9):1507-18. PubMed ID: 9815837
[TBL] [Abstract][Full Text] [Related]
4. [Ifosfamide induced encephalopathy: 15 observations].
Dufour C; Grill J; Sabouraud P; Behar C; Munzer M; Motte J; Oberlin O; Paci A; Hartmann O
Arch Pediatr; 2006 Feb; 13(2):140-5. PubMed ID: 16364615
[TBL] [Abstract][Full Text] [Related]
5. Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide.
Mace JR; Keohan ML; Bernardy H; Junge K; Niebch G; Romeis P; Thoma A; Wagner T; Mueller U; Demetri G; Baker LH
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5829-34. PubMed ID: 14676103
[TBL] [Abstract][Full Text] [Related]
6. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
7. Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma.
Lind MJ; Margison JM; Cerny T; Thatcher N; Wilkinson PM
Cancer Res; 1989 Feb; 49(3):753-7. PubMed ID: 2910494
[TBL] [Abstract][Full Text] [Related]
8. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature.
Pelgrims J; De Vos F; Van den Brande J; Schrijvers D; Prové A; Vermorken JB
Br J Cancer; 2000 Jan; 82(2):291-4. PubMed ID: 10646879
[TBL] [Abstract][Full Text] [Related]
9. Urinary excretion of ifosfamide, 4-hydroxyifosfamide, 3- and 2-dechloroethylifosfamide, mesna, and dimesna in patients on fractionated intravenous ifosfamide and concomitant mesna therapy.
Kurowski V; Wagner T
Cancer Chemother Pharmacol; 1997; 39(5):431-9. PubMed ID: 9054957
[TBL] [Abstract][Full Text] [Related]
10. A phase I study of prolonged ambulatory infusion of Ifosfamide with oral mesna.
Olver I; Keefe D; Myers M; Caruso D
Chemotherapy; 2005 May; 51(2-3):142-6. PubMed ID: 15886474
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of (mono)amine oxidase activity and prevention of ifosfamide encephalopathy by methylene blue.
Aeschlimann C; Cerny T; Küpfer A
Drug Metab Dispos; 1996 Dec; 24(12):1336-9. PubMed ID: 8971139
[TBL] [Abstract][Full Text] [Related]
12. Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study.
You B; Tranchand B; Girard P; Falandry C; Ribba B; Chabaud S; Souquet PJ; Court-Fortune I; Trillet-Lenoir V; Fournel C; Tod M; Freyer G
Lung Cancer; 2008 Nov; 62(2):261-72. PubMed ID: 18442869
[TBL] [Abstract][Full Text] [Related]
13. High-dose ifosfamide with mesna and granulocyte-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma.
Talbot SM; Rankin C; Taub RN; Balcerzak SP; Bhoopalam N; Chapman RA; Baker LH; Middleman EL; Antman KH
Cancer; 2003 Jul; 98(2):331-6. PubMed ID: 12872353
[TBL] [Abstract][Full Text] [Related]
14. Hydration, methylene blue, and thiamine as a prevention regimen for ifosfamide-induced encephalopathy.
Gharaibeh EZ; Telfah M; Powers BC; Salacz ME
J Oncol Pharm Pract; 2019 Oct; 25(7):1784-1786. PubMed ID: 30348070
[TBL] [Abstract][Full Text] [Related]
15. DICE (dexamethasone, ifosfamide, cisplatin, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma (NHL).
Coleman M; Leonard J; Shuster MW; Kaufman TP
Eur J Haematol Suppl; 2001 Jul; 64():41-5. PubMed ID: 11486401
[TBL] [Abstract][Full Text] [Related]
16. Phase I clinical and pharmacokinetic study of combination chemotherapy with topotecan and ifosfamide in patients with progressive or relapsed solid tumors.
Schneider CP; Merkel U; Grübner U; Kath R; Höffken K; Hoffmann A
J Cancer Res Clin Oncol; 2002 Jun; 128(6):313-8. PubMed ID: 12073049
[TBL] [Abstract][Full Text] [Related]
17. Ifosfamide- and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma.
Mayer J; Vásová I; Korístek Z; Navrátil M; Klabusay M; Doubek M; Vorlícek J; Cernilová I; Vodvárka P; Petráková K
Eur J Haematol Suppl; 2001 Jul; 64():21-7. PubMed ID: 11486396
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck.
Shin DM; Glisson BS; Khuri FR; Lippman SM; Ginsberg L; Diaz E; Papadimitrakopoulou V; Feng L; Francisco M; Garden A; Kies MS; Myers J; Clayman G; Hong WK
Cancer; 2002 Jul; 95(2):322-30. PubMed ID: 12124833
[TBL] [Abstract][Full Text] [Related]
19. Combined intravenous and oral mesna in outpatients treated with ifosfamide.
Goren MP; McKenna LM; Goodman TL
Cancer Chemother Pharmacol; 1997; 40(5):371-5. PubMed ID: 9272112
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of cyclophosphamide and thiotepa in a conventional fractionated high-dose regimen compared with a novel simplified unfractionated regimen.
Ekhart C; Rodenhuis S; Beijnen JH; Huitema AD
Ther Drug Monit; 2009 Feb; 31(1):95-103. PubMed ID: 19155964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
